Category: Conferences
Search News
IBIS-II – new results from international breast cancer study
12th December 2019
The Queen Mary University of London professor leading an international breast cancer study says anastrozole – rather than tamoxifen – should be the preventive drug-of-choice for post-menopausal women at increased risk of developing the disease.
Read more
KEYNOTE-522: Immune therapy for breast cancer
30th September 2019
Results of an interim analysis from the KEYNOTE-522 trial have shown a treatment combination of immunotherapy plus chemotherapy to improve response rates in patients with early triple-negative breast cancer. Prof Peter Schmid presented the results at the ESMO Congress 2019 in Barcelona, Spain.
Read more
World Economic Forum, China
8th July 2019
Professor Fran Balkwill was selected as a high-level delegation to the World Economic Forum in Dalian, China, to discuss her work in cancer research. As one of three researchers selected by the European Research Council to attend, she participated in presentations, panel discussions and press conferences on the topic of ‘Tackling cancer from within – new perspectives’.
Read more
2019 ASCO Annual Meeting
4th June 2019
Professor Peter Schmid, Lead of the Centre for Experimental Cancer Medicine at the Barts Cancer Institute, Queen Mary University of London, attended this year’s ASCO Annual Meeting and today presented updated survival data from the IMpassion130 trial.
Read more
BCI at the 60th ASH Annual Meeting
14th January 2019
Researchers from our Centre for Haemato-Oncology attended the 60th American Society of Hematology (ASH) Annual Meeting and Exposition to showcase our blood cancer research.
Read more
BCI at the 2018 ASCO Annual Meeting: Results from the PAKT and ABACUS trials
15th June 2018
Professors Peter Schmid and Thomas Powles attended this year’s ASCO Annual Meeting, which took place from 1st-5th June in Chicago. Prof Schmid, presented data from the PAKT trial- a trial investigating the addition of a novel drug called AZD5363 to a standard chemotherapy regimen as a treatment for triple-negative breast cancer (TNBC). Prof Powles presented results from the ABACUS trial, which is investigating the efficacy and safety of a drug called atezolizumab administered prior to cystectomy in muscle invasive bladder cancer. The ABACUS trial was selected as one of the highlights of this year’s meeting.
Read more